NASDAQ : ANGN

Angion Biomedica Corp.

$1 USD

$0 (0.0%)

Volume
224.8K
Average Volume
9.65K
Market Capitalization
$30.11M
P/E Ratio
-0.42
Dividend Yield
0.00%
Price Target
$1.50
Year High
$20.40
Year Low
$1.00
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$2.24
Company Overview

NASDAQ

Jay R. Venkatesan

Biotechnology

Healthcare

ANGN

3

US

USD

https://www.angion.com

415 655 4899

03476J107

0001601485

Liquidity Metrics

-3.39

2.24

2.24

2.07

0.00

Sales & Valuation

-$

0.00

-12.67

-0.78

-2.11

Profitability

-$2.58

-$39.57M

0.00%

0.00%

-2748.16%

-177.11%

P/E Metrics

-0.42

-0.03

-0.03

Analyst Price Target & Rating

$1.50

$1.50

$1.50

N/A

0/5

4 Analysts

-33.33%

Financial Health Scores

-17.97

3/9

$8.97M

$22.69M

$24.13M

-$27.82M

Key Metrics (TTM)

$20.03M

0.00

-0.75

2.24

-2748.16%

-227.73%

-220.65%

-127.83%

0 days

Company Executives
Name Title
Jennifer J. Rhodes Executive Vice President, Chief Bus. Officer, Gen. Counsel, Chief Compliance Officer & Sec.
Daniel Iazzetti Vice President of HR
Jay R. Venkatesan Pres, Chief Executive Officer & Chairman
Bruce Rich Assistant Sec.
Gregory S. Curhan Chief Financial Officer
Poll Results

No votes yet today — be the first to share your view!

About Angion Biomedica Corp. (NASDAQ:ANGN) Stock

Angion Biomedica Corp. operates as a biopharmaceutical enterprise, concentrating its efforts on the identification, advancement, and market introduction of small molecule treatments for severe organ damage and scarring conditions. Its primary investigational compound, ANG-3070, is an orally administered tyrosine kinase receptor inhibitor currently being developed to address fibrotic ailments, particularly those impacting the kidneys and lungs. The company's product pipeline also features ANG-3777, a hepatocyte growth factor mimetic engineered to treat acute organ injuries like delayed graft function, in addition to initiatives for ROCK2 inhibitors targeting fibrotic diseases and a CYP11B2 inhibitor program. Established in 1998, Angion Biomedica Corp. maintains its headquarters in Uniondale ... , New York.

Frequently Asked Questions

What is the current Angion Biomedica Corp. (ANGN) stock price?

Angion Biomedica Corp.(NASDAQ:ANGN) stock price is $1 in the last trading session. During the trading session, ANGN stock reached the peak price of $20.4 while $1.0 was the lowest point it dropped to. The percentage change in ANGN stock occurred in the recent session was 0.0% while the dollar amount for the price change in ANGN stock was $0.

ANGN's industry and sector of operation?

The NASDAQ listed ANGN is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of ANGN?

Jennifer J. Rhodes | Executive Vice President, Chief Bus. Officer, Gen. Counsel, Chief Compliance Officer & Sec.
Daniel Iazzetti | Vice President of HR
Jay R. Venkatesan | Pres, Chief Executive Officer & Chairman
Bruce Rich | Assistant Sec.
Gregory S. Curhan | Chief Financial Officer

How many employees does ANGN have?

Number of ANGN employees currently stands at 3. ANGN operates from 51 Charles Lindbergh Boulevard, Uniondale, NY 11553, US.

Link for ANGN official website?

Official Website of ANGN is: https://www.angion.com

How do I contact ANGN?

ANGN could be contacted at phone #415 655 4899 and can also be accessed through its website. ANGN operates from 51 Charles Lindbergh Boulevard, Uniondale, NY 11553, US.

How many shares of ANGN are traded daily?

The average number of ANGN shares traded daily for last 3 months was 9.65K.

What is the market cap of ANGN currently?

The market value of ANGN currently stands at $30.11M with its latest stock price at $1